I have a question on the occupancy. Like in your opening remarks, you highlighted that improving occupancy and service mix is one of the areas that you are working on. So, can you highlight some near-term and medium-term levers for the occupancy improvement and service mix improvement?
Are there segments withi n health care, like within the pediatric care that you currently do not have presence in and are intending to build presence in those categories?
During the quarter, did we kind of book any shelf stock adjustment for Revlimid?
Okay. And second, on generic Ventolin launch that you are expected to do next month. So just wanted to understand if the Innovator is supposed to launch a green version of Ventolin sometime by third quarter of this financial year. So hypothetically, if the innovator is replaced - - is able to replace all of their Ventolin product with the new version, would that impact Cipla?
So I have a question on Revlimid. Since you are expecting kind of immaterial volumes in Q3, so is it fair to say like for FY '26, our overall Revlimid sales would be less than 50% of what it was in FY '25?
So any color on the value decline that we'll see this year, maybe 25%? Is that -- would that be a fair...
Thanks for the opportunity. So, on Abatacept filing, whether you'll be filing both the IV and the subcutaneous versions in December 2025?
So, subcutaneous is the beginning of '28.
Good evening and thanks for the opportunity. On rituximab biosimilar launch in Europe, would you be selling on your own? Or you would have a partner there? And how long would you take to ramp that up to its full potential?
And would this be a $100 million plus opportunity for you?
In India, in the Cardiac and the pain segment, can you share the growth of the covered market and Ajanta Pharma's growth?
Q2.
Sir, on the cardiac and critical care markets where you are focusing in India. Would you have a number as to how large these markets are?
Got it. So secondly, in the U.S. recently, we heard they have raised import duties on certain medical devices that they import from China. Any positive impact Poly Medicure could have because of the import duty?
Thanks for the opportunity. Sir with respect to th e new medical device regulation you shared that class A, class B devices would be regulated by the state regulators and the class C and D would be so could you share has this in anyway impacted existing competition so basically have competitors exited the market.
Just a follow up on this so should I understand Poly Medicure already has approval from the regulator.
Hi, good evening and thanks for the opportunity. A question on your pending ANDAs and NDAs. So, you have 116 AND As pending and about 14 NDAs pending approval. Would you be able to share how many of these are from sites that are impacted by OAI?
In the sense, like just a percentage of the spending AND As or NDAs that would be filed from the affected sites?
Yes. Thanks for the opportunity and good evening, everyone. With respect to generic Revlimid, we are almost halfway through into CY'25. And there are two quarters to go before the exclusivity expires. So is it fair to assume that you would have sold 50% of your allocated volume quota for the year?
Okay. So, do we expect our U.S. formulation run rate to improve from here in the coming quarters?
I have a question on the balance sheet. If I look at the other current assets, it's almost doubled since , March '25 from INR2,500 crores to almost INR5,000 crores. Could you clarify on this? What led to this?
Sorry, which settlement?
On Ilumya, would you be able to share what would be its market share in the biologics category for psoriasis?
Yes, in the US, right.
I have a question on deuruxolitinib. So wanted to understand whether the product would be used by patients chronically or would this be a sub-chronic treatment wherein patients would only use it until they recover the hair loss?
Just one more, whether we'll be able to launch deuruxolitinib post approval immediately? Or would there be a patent that would block the launch?
I've a question on SEZABY, so do you expect the U.S. FDA anytime this year to allow you market exclusivity under the DESI Act?
Okay. Okay. And a second question on Winlevi. If you could share what percentage of the prescriptions are still under the patient assistance program?